High-Value Cancer Care and the Problem With Surrogate Endpoints in the Quality/Cost Equation

被引：0
作者：
Chino, Fumiko [1 ]
机构：
[1] Mem Sloan Kettering, Radiat Oncol, New York, NY 10021 USA
来源：
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2019年 / 17卷 / 12期
关键词：
ONCOLOGY VALUE FRAMEWORK; AMERICAN SOCIETY; SURVIVAL;
D O I：
10.6004/jnccn.2019.7372
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1569 / 1570
页数：2
相关论文
共 10 条
  • [1] An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate
    Chen, Emerson Y.
    Raghunathan, Vikram
    Prasad, Vinay
    [J]. JAMA INTERNAL MEDICINE, 2019, 179 (07) : 915 - 921
  • [2] Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials
    Chen, Emerson Y.
    Joshi, Sunil K.
    Tran, Audrey
    Prasad, Vinay
    [J]. JAMA INTERNAL MEDICINE, 2019, 179 (05) : 642 - 647
  • [3] Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?
    Cheng, Sierra
    Cheung, Matthew C.
    Jiang, Di Maria
    McDonald, Erica
    Arciero, Vanessa S.
    Ezeife, Doreen Anuli
    Rahmadian, Amanda
    Chambers, Alexandra
    Sabarre, Kelley-Anne
    Parmar, Ambika
    Chan, Kelvin K. W.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (12): : 1489 - +
  • [4] A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
    Haslam, Alyson
    Hey, Spencer P.
    Gill, Jennifer
    Prasad, Vinay
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 106 : 196 - 211
  • [5] Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points
    Kay, A.
    Higgins, J.
    Day, A. G.
    Meyer, R. M.
    Booth, C. M.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (06) : 1646 - 1651
  • [6] Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals
    Kim, Chul
    Prasad, Vinay
    [J]. JAMA INTERNAL MEDICINE, 2015, 175 (12) : 1992 - 1994
  • [7] Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents
    Saad, E. D.
    Buyse, M.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (03) : 373 - 378
  • [8] Assessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: An Analysis of Randomized Clinical Trials
    Saluja, Ronak
    Everest, Louis
    Cheng, Sierra
    Cheung, Matthew
    Chan, Kelvin K. W.
    [J]. JAMA ONCOLOGY, 2019, 5 (08) : 1188 - 1194
  • [9] Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
    Schnipper, Lowell E.
    Davidson, Nancy E.
    Wollins, Dana S.
    Blayney, Douglas W.
    Dicker, Adam P.
    Ganz, Patricia A.
    Hoverman, J. Russell
    Langdon, Robert
    Lyman, Gary H.
    Meropol, Neal J.
    Mulvey, Therese
    Newcomer, Lee
    Peppercorn, Jeffrey
    Polite, Blase
    Raghavan, Derek
    Rossi, Gregory
    Saltz, Leonard
    Schrag, Deborah
    Smith, Thomas J.
    Yu, Peter P.
    Hudis, Clifford A.
    Vose, Julie M.
    Schilsky, Richard L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (24) : 2925 - +
  • [10] Challenges in the Clinical Application of the American Society of Clinical Oncology Value Framework: A Medicare Cost-Benefit Analysis in Chronic Lymphocytic Leukemia
    Seymour, Erlene K.
    Schiffer, Charles A.
    de Souza, Jonas A.
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (12) : E1002 - E1011
1